Scholar Rock(SRRK) - 2025 Q4 - Annual Report

Regulatory Approval and Compliance - The regulatory approval process for apitegromab in the U.S. and EU is lengthy and unpredictable, with a Complete Response Letter (CRL) received from the FDA in September 2025 requiring resubmission of the Biologics License Application (BLA) [350]. - The CRL has delayed progress toward potential commercialization of apitegromab, impacting the ongoing regulatory review of the Marketing Authorization Application (MAA) by the EMA [352]. - Changes or disruptions at the FDA and other regulatory agencies could negatively impact the timely review and approval of the BLA upon resubmission [358]. - The company may face challenges in reaching agreements with regulatory authorities on clinical trial designs, which could delay marketing approvals [363]. - Regulatory approvals for apitegromab may be subject to limitations on approved uses and requirements for post-market testing [401]. - The FDA may reevaluate the Orphan Drug Act, introducing uncertainty regarding future regulatory impacts on the company's business [387]. - The company must comply with extensive regulatory requirements, including cGMP regulations, which may result in significant costs and ongoing obligations [400]. - Compliance with Good Clinical Practice (GCP) requirements is essential, and any failure could result in unreliable clinical data and regulatory scrutiny [379]. - The company is conducting clinical trials for apitegromab, including a long-term extension trial (ONYX) and a Phase 2 trial in children under two with SMA, which are subject to European privacy laws and the GDPR [460]. - The GDPR imposes fines of up to €20 million (approximately $21.5 million) or up to 4% of total worldwide annual turnover for serious offenses, increasing compliance costs and legal risks [460]. - The company faces potential civil, criminal, and administrative penalties for non-compliance with health care privacy and data protection laws, which could negatively affect operating results [459]. - The evolving regulatory landscape regarding data protection, particularly between the UK and EEA, may increase legal risk and complexity for the company [462]. - The company must comply with various state laws in the U.S. that may be more stringent than federal laws, such as the CCPA, which imposes comprehensive privacy rights and obligations [465]. Financial Performance and Capital Needs - The company has incurred net losses every year since inception and anticipates continued net losses in the future [346]. - The company will require additional capital to fund operations and complete the development and commercialization of apitegromab and other product candidates [348]. - The company's future financial performance and ability to commercialize apitegromab, if approved, will depend on effectively managing growth activities [434]. - Coverage and reimbursement for apitegromab, if approved, are uncertain and critical for profitability, as third-party payors may not provide adequate reimbursement [486]. - Changes in healthcare legislation and regulatory initiatives could limit reimbursement amounts, impacting demand for pharmaceutical products [491]. - The company may face substantial civil and criminal penalties for failing to comply with international business laws, including potential suspension from government contracting [475]. Clinical Development and Trials - Clinical development is expensive and can take many years, with inherent uncertainties leading to potential delays in trials and regulatory approvals [362]. - The company anticipates that future trials may utilize an open-label design, which could introduce biases affecting the perceived efficacy of treatments [365]. - Delays in clinical testing or marketing approvals could significantly increase product development costs and shorten exclusive commercialization periods [366]. - The company is developing apitegromab for FSHD, a rare disease affecting approximately 30,000 people in the U.S. and Europe, which may complicate patient enrollment in clinical trials [374]. - Difficulties in patient enrollment could lead to increased costs and adversely affect the timing or outcomes of clinical trials [375]. - The company relies heavily on third parties for conducting clinical trials, which may lead to delays if these parties do not meet their contractual obligations [376]. - Interim results from clinical trials are subject to change as more data becomes available, which could impact the perceived success of the trials [371]. - The results from preclinical studies and early-stage trials may not predict future outcomes, leading to potential setbacks in later-stage trials [372]. - The company may encounter delays in clinical trials due to reliance on third-party CROs, which could materially impact development timelines [382]. Market and Competitive Landscape - The biopharmaceutical industry is highly competitive, with many companies having greater resources and experience, which could impact the commercial opportunity for apitegromab [413]. - Market acceptance of apitegromab is uncertain, and failure to achieve sufficient acceptance could adversely affect revenue generation and profitability [407]. - Apitegromab's efficacy and safety have been demonstrated in clinical trials, with competitive pricing and market introduction timing being critical factors for its success [411]. - The company may face challenges in establishing sales and marketing capabilities or entering agreements with third parties for apitegromab commercialization [409]. - The company faces significant competition in securing partnerships, and recent business combinations among large pharmaceutical companies have reduced potential collaborators [508]. Intellectual Property and Legal Risks - The patenting process is complex and costly, and failure to secure adequate patent protection could allow competitors to develop similar products [510]. - Noncompliance with patent maintenance requirements could result in the loss of patent rights, impacting the company's market position [517]. - The ongoing conflict in Ukraine may create uncertainties regarding patent protection and enforcement in the region, potentially allowing competitors to enter the market [518]. - The company is dependent on third-party licensed intellectual property, and failure to comply with license obligations could result in significant rights loss [521]. - The company may face challenges in maintaining and prosecuting in-licensed patents, which could impact the validity and enforceability of these rights [522]. - Disputes with licensors regarding intellectual property could impair the company's ability to develop and commercialize product candidates [523]. - The company may struggle to obtain necessary rights for future product candidates, which could hinder business growth [524]. - The company may need to provide companion diagnostic tests for product candidates, which could be covered by third-party intellectual property rights [527]. - The competitive landscape for acquiring third-party intellectual property rights may disadvantage the company compared to more established firms [529]. - Changes in patent law could diminish patent value and impair the company's ability to protect its products [530]. - Third-party claims of intellectual property infringement could delay product development and result in costly litigation [536]. Operational and Management Challenges - The company relies on third-party manufacturers for clinical and commercial supplies, which may lead to risks related to supply limitations or quality issues [348]. - The company expects to invest significant resources to establish compliance, medical affairs, and commercial organizations for marketing apitegromab, if approved [356]. - The company expects to hire additional personnel to support the commercialization of apitegromab as it approaches market readiness [433]. - Attracting and retaining qualified management and scientific personnel is critical, as competition in the biopharmaceutical space is intense, potentially increasing costs [438]. - Changes in executive or senior management could disrupt business operations and adversely affect financial condition and results [439]. - Cybersecurity risks are heightened due to reliance on third-party IT systems, which could lead to material disruptions in development programs [441]. - Economic uncertainty, high inflation, and geopolitical instability may adversely affect the company's business and supply chains [429]. Collaboration and Partnership Risks - The company may seek collaborations for product candidates like apitegromab, but failure to secure such partnerships could adversely affect business operations [503]. - Collaborations may pose risks, including potential delays in clinical trials and insufficient funding for development programs [505].